Alpha Tau's Cancer Trials Keep Beating Expect...
WSW, NY, September 15th, 2026, FinanceWire
A head and neck cancer trial was stopped early because the results were so strong the study had already proven its point. A brain cancer study where two out of three patients saw their tumors disappear entirely. A pancreatic cancer trial that expanded from 12 patients to 48 because so many doctors wanted their patients in it. Alpha Tau Medical Ltd. (NASDAQ: DRTS) is generating a pattern of early clinical results that keep exceeding what the trials were designed to test, and the next few months could determine whether that pattern holds at scale.
The head and neck results may be the most striking. Alpha Tau's study combining its Alpha DaRT therapy with pembrolizumab, a widely used immunotherapy drug, was stopped after surpassing its pre-specified threshold for success. Among nine evaluable patients with advanced head and neck cancer, every one responded to treatment: a 100% response rate, meaning every patient's tumor either shrank or disappeared. Median overall survival reached 18.2 months, compared to 12.3 months when pembrolizumab is used alone. The combination's response rate was more than five times the 19% typically seen with the drug by itself. No serious Alpha DaRT-related side effects were reported.
Those results would be noteworthy on their own. But they are part of a broader pattern across Alpha Tau's programs.
In recurrent glioblastoma, an aggressive form of brain cancer with few effective treatments, Alpha Tau's REGAIN trial reported that every tumor either shrank or stopped growing in the first three patients treated. Two patients achieved complete responses, meaning their tumors disappeared entirely on imaging, and the third saw a 30% tumor reduction. The FDA subsequently cleared the trial to finish enrolling its remaining seven patients across additional U.S. academic centers.
In pancreatic cancer, the story is one of physician demand. Alpha Tau's IMPACT study originally planned to enroll 12 patients. Demand from treating doctors led to three separate FDA-approved expansions, and on August 31 the company announced it had completed enrollment at 48 patients across 10 centers in the United States, Canada, and Israel. CEO Uzi Sofer called it "probably the fastest enrollment in my memory as CEO." Earlier data from Alpha Tau's pancreatic trials had shown patients with metastatic disease, the most advanced form, surviving a median of 11.2 months on Alpha DaRT with chemotherapy, against a historical baseline of four to six months.
Alpha Tau is the developer of Alpha DaRT, an alpha-radiation cancer therapy delivered directly into a tumor. Tiny radioactive sources are placed inside the growth, and as they decay they release short-range particles that damage nearby cancer cells while traveling too short a distance to harm surrounding healthy tissue. Treatment is delivered in a single outpatient session, often through endoscopic ultrasound, the same procedure gastroenterologists already use every day.
What makes the next few months particularly significant is that three of Alpha Tau's most advanced programs are approaching data milestones in one narrow window. ReSTART, the company's 88-patient pivotal trial in a common form of skin cancer called recurrent cutaneous squamous cell carcinoma, could deliver initial results by late 2026 or early 2027. IMPACT data from all 48 pancreatic cancer patients is expected in early 2027. And additional brain cancer results from REGAIN could arrive around year-end.
Each readout carries different stakes. ReSTART is the closest to an FDA milestone: it holds a Breakthrough Device Designation, and the first section of the company's approval application was submitted in January. IMPACT could help establish Alpha DaRT as a meaningful option in one of the deadliest cancers in medicine, a disease where survival times for patients with advanced disease have barely improved in decades. REGAIN, still early at 10 patients by design, could confirm whether the striking early responses hold across a broader group.
The company enters this stretch with $104.8 million in cash as of June 30, a 20-year exclusive U.S. commercialization partnership with Tolmar for prostate cancer secured earlier this year, and a licensed manufacturing facility in Hudson, New Hampshire with capacity for roughly 400,000 Alpha DaRT sources annually.
Whether the coming data confirms the early signals or introduces new questions, the next two quarters could shape Alpha Tau's trajectory for years to come. For a clinical-stage company generating this kind of result across brain, pancreatic, skin, and head and neck cancers simultaneously, the window ahead may not stay quiet for long.
Recent News Highlights from Alpha Tau Medical Ltd. (NASDAQ: DRTS)
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from Alpha Tau Medical Ltd. (the “Issuer”) for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer’s products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer’s public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.
Contact
Wall Street Wirecoverage@wallstwire.ai